InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,650.41
(
1.18%
)
US TECH 100
19,973.60
(
1.51%
)
Dow Jones
40,196.90
(
1.11%
)
Brent Oil
84.85
(
-0.31%
)
Bitcoin
58,114.65
(
1.33%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

grandma_of_jbraika

Send PM Follow Ignore
Followers 5
Posts 593
Boards Moderated 0
Alias Born 06/11/2010

grandma_of_jbraika

Re: BTH post# 1860

Tuesday, 09/14/2010 9:12:14 AM

Tuesday, September 14, 2010 9:12:14 AM

Post# of 80490
"We have had a productive start to the year with substantial progress advancing each of our internally discovered drug candidates and the successful completion of our revised agreement with Merck on the development, manufacture and commercialization of ridaforolimus, our investigational mTOR inhibitor," stated Harvey J. Berger, M.D. chairman and chief executive officer of ARIAD. "We expect several key business and clinical catalysts during the remainder of 2010, each one with the potential to create significant value for our shareholders."

Did Harvey state that 12 months or more ago? Ridaforolimus failure? What else will you negate ARIA? FMR dumping? Dilution? The CEO ... ?
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up